May 4 (Reuters) - Regeneron Pharmaceuticals reported a 13% fall in quarterly profit on Wednesday, as sales of its COVID-19 antibody cocktail were hit by the U.S. health regulator's decision to limit their use. (Reporting by Leroy Leo in Bengaluru; Editing by Rashmi Aich and Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
985 USD | +0.45% | +0.28% | +12.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.15% | 11TCr | |
+12.30% | 12TCr | |
-8.14% | 2.34TCr | |
-1.69% | 2.18TCr | |
-10.60% | 1.81TCr | |
-41.25% | 1.67TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr | |
-31.18% | 754.84Cr |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron quarterly profit drops as COVID antibody sales hit